Immunobiology of Pediatric Tuberculosis

Lessons Learned and Implications for an Improved TB-Vaccine

Research output: Contribution to journalArticle

Abstract

Children, especially neonates and young infants, are uniquely vulnerable to tuberculosis (TB) and frequently present with primary progressive pulmonary or disseminated disease. There is an urgent need to understand the unique immunobiology of Mycobacterium tuberculosis ( Mtb ) in young infants and to identify protective infant immune responses. The existing vaccine against TB, Mycobacterium bovis bacillus Calmette–Guérin ( M. bovis BCG), provides a partial protection against TB disease and disseminated forms of TB in infants; however, it is unknown how this partial protection is mediated. To end pediatric TB morbidity and mortality, a fully efficacious next-generation TB-vaccine is needed. Here, we focus on our current understanding of TB immunobiology as it pertains to young infants, and we evaluate what BCG-vaccination, as well as recently trialed novel TB-vaccines, has taught us about the immunobiology of mycobacterial infection in this population.

Original languageEnglish (US)
JournalJournal of Pediatric Infectious Diseases
DOIs
StateAccepted/In press - Apr 27 2017

Fingerprint

Tuberculosis Vaccines
Tuberculosis
Pediatrics
Mycobacterium bovis
Mycobacterium tuberculosis
Bacillus
Vaccination
Newborn Infant
Morbidity
Lung
Mortality
Infection
Population

Keywords

  • BCG
  • immune response
  • Immunity
  • infant
  • Mtb
  • pediatric
  • T cell
  • tuberculosis
  • vaccine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Cite this

@article{e3838ad2c63f420fa42061f676e66634,
title = "Immunobiology of Pediatric Tuberculosis: Lessons Learned and Implications for an Improved TB-Vaccine",
abstract = "Children, especially neonates and young infants, are uniquely vulnerable to tuberculosis (TB) and frequently present with primary progressive pulmonary or disseminated disease. There is an urgent need to understand the unique immunobiology of Mycobacterium tuberculosis ( Mtb ) in young infants and to identify protective infant immune responses. The existing vaccine against TB, Mycobacterium bovis bacillus Calmette–Gu{\'e}rin ( M. bovis BCG), provides a partial protection against TB disease and disseminated forms of TB in infants; however, it is unknown how this partial protection is mediated. To end pediatric TB morbidity and mortality, a fully efficacious next-generation TB-vaccine is needed. Here, we focus on our current understanding of TB immunobiology as it pertains to young infants, and we evaluate what BCG-vaccination, as well as recently trialed novel TB-vaccines, has taught us about the immunobiology of mycobacterial infection in this population.",
keywords = "BCG, immune response, Immunity, infant, Mtb, pediatric, T cell, tuberculosis, vaccine",
author = "Boer, {Mardi C.} and Deborah Lewinsohn and Christina Lancioni",
year = "2017",
month = "4",
day = "27",
doi = "10.1055/s-0037-1607233",
language = "English (US)",
journal = "Journal of Pediatric Infectious Diseases",
issn = "1871-0336",
publisher = "IOS Press",

}

TY - JOUR

T1 - Immunobiology of Pediatric Tuberculosis

T2 - Lessons Learned and Implications for an Improved TB-Vaccine

AU - Boer, Mardi C.

AU - Lewinsohn, Deborah

AU - Lancioni, Christina

PY - 2017/4/27

Y1 - 2017/4/27

N2 - Children, especially neonates and young infants, are uniquely vulnerable to tuberculosis (TB) and frequently present with primary progressive pulmonary or disseminated disease. There is an urgent need to understand the unique immunobiology of Mycobacterium tuberculosis ( Mtb ) in young infants and to identify protective infant immune responses. The existing vaccine against TB, Mycobacterium bovis bacillus Calmette–Guérin ( M. bovis BCG), provides a partial protection against TB disease and disseminated forms of TB in infants; however, it is unknown how this partial protection is mediated. To end pediatric TB morbidity and mortality, a fully efficacious next-generation TB-vaccine is needed. Here, we focus on our current understanding of TB immunobiology as it pertains to young infants, and we evaluate what BCG-vaccination, as well as recently trialed novel TB-vaccines, has taught us about the immunobiology of mycobacterial infection in this population.

AB - Children, especially neonates and young infants, are uniquely vulnerable to tuberculosis (TB) and frequently present with primary progressive pulmonary or disseminated disease. There is an urgent need to understand the unique immunobiology of Mycobacterium tuberculosis ( Mtb ) in young infants and to identify protective infant immune responses. The existing vaccine against TB, Mycobacterium bovis bacillus Calmette–Guérin ( M. bovis BCG), provides a partial protection against TB disease and disseminated forms of TB in infants; however, it is unknown how this partial protection is mediated. To end pediatric TB morbidity and mortality, a fully efficacious next-generation TB-vaccine is needed. Here, we focus on our current understanding of TB immunobiology as it pertains to young infants, and we evaluate what BCG-vaccination, as well as recently trialed novel TB-vaccines, has taught us about the immunobiology of mycobacterial infection in this population.

KW - BCG

KW - immune response

KW - Immunity

KW - infant

KW - Mtb

KW - pediatric

KW - T cell

KW - tuberculosis

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85031499115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031499115&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1607233

DO - 10.1055/s-0037-1607233

M3 - Article

JO - Journal of Pediatric Infectious Diseases

JF - Journal of Pediatric Infectious Diseases

SN - 1871-0336

ER -